TFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.	:	07/402,450	Confirmation No.: 8131
Applicant	:	George J. MURAKAWA et al.	
Filed	:	1 September 1989	
TC/A.U.	:	1631	
Examiner	:	Marina Miller	
Attorney Docket No.	:	2124-154	
Customer No.	:	6449	

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION OF JOHN J. ROSSI

I, John J. Rossi, Ph.D., declare as follows:

1. I am a coinventor of the above-identified application. The other joint inventors of the above-identified application are George J. Murakawa, R. Bruce Wallace and John A. Zaia.

2. I received a Bachelor's Degree from the University of New Hampshire in 1969 and a Ph.D. Degree from _the University of Connecticut at Storrs in 1976. My formal training was in genetics, and now I focus on molecular genetics of human cells. In particular I study RNA interference and its potential as a novel theapeutic for the treatment of HIV infection. My lab was the first to publish an RT-PCR based method for detection of HIV in human blood samples. We continue to use this technology in our efforts to treat HIV infection.

3. I am a co-author of the following papers which have been cited in an Information Disclosure Statement in the above-identified application:

Zaia, J.A. and Rossi, J.J. (1989). Confirmation of HIV infection using gene amplification. *Transfusion Medicine Reviews* **3**(1), Suppl. 1:27-30. [hereinafter Zaia et al. (1989a)]

Zaia, J.A. and Rossi, J.J. (1989). Confirmation of HIV infection using gene amplification. *TestTrends* **3**(1):4-5. [hereinafter Zaia et al. (1989b)]

4. The other co-author of the above-identified papers is John A. Zaia.

5. I believe that I, along with George J. Murakawa, R. Bruce Wallace and John A. Zaia, am an original, first and joint inventor of the subject matter described and claimed in the above-identified application, and of the subject matter disclosed on page 29 of Zaia et al. (1989a) with respect to quantitation, and of the subject matter disclosed on page 5 of Zaia et al. (1989b) with respect to quantitiation, specifically the simultaneous amplification of a target viral RNA sequence that may be present in a sample and a reference RNA sequence in which the reference RNA sequence differs in length and in which a known amount of the reference RNA sequence is used for the quantitation of the target viral RNA sequence.

6. The description at page 29 of Zaia et al. (1989a) with respect to quantitation, and of the subject matter disclosed on page 5 of Zaia et al. (1989b) with respect to quantitiation originated with the joint inventors of the above-identified application.

7. I declare further that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true, and further that these statements are made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false testimony may jeopardize the validity of the Murakawa application or any patent resulting thereon.

Date Nov. 22, 2005

John J. Rossi, Ph.D.

2124-154.Rossi.Decl.doc